Almirall and BioFocus enter Research Alliance
Complete the form below to unlock access to ALL audio articles.
Under the terms of the collaboration, BioFocus will apply its integrated drug discovery capabilities whilst Almirall will bring in respiratory specific knowhow to the joint experimental effort. The value of this collaboration to BioFocus could reach €7.5 million.
“We selected BioFocus for this alliance because of the excellent technology and scientific fit between both companies,” said Dr. Bertil Lindmark, CSO, Executive Director R&D of Almirall.
“We are delighted to form a drug discovery alliance with one of Europe’s leading research-based pharmaceutical companies,” added Dr. Chris Newton, SVP Galapagos Services and Managing Director, BioFocus.
Respiratory is a key research focus for Almirall together with gastrointestinal and dermatology areas where the company is especially engaged to offer new therapeutic solutions.
